A one quarter event. One bad earnings report after several good ones in row. Gilead Sciences will recover, back to $100 and above. Perrigo Company plc (PRGO) is also on sale. Valeant Pharma (VRX) is approaching value. Allergan plc (AGN) is too inexpensive to ignore. Agree or disagree?